Bank of New York Mellon Corp grew its stake in Catalyst Biosciences Inc (NASDAQ:CBIO) by 86.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,811 shares of the biopharmaceutical company’s stock after acquiring an additional 26,829 shares during the period. Bank of New York Mellon Corp owned 0.48% of Catalyst Biosciences worth $675,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. raised its stake in shares of Catalyst Biosciences by 7.3% in the first quarter. BlackRock Inc. now owns 186,148 shares of the biopharmaceutical company’s stock worth $4,802,000 after acquiring an additional 12,685 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Catalyst Biosciences during the second quarter worth approximately $1,225,000. Millennium Management LLC bought a new stake in shares of Catalyst Biosciences during the first quarter worth approximately $1,620,000. Northern Trust Corp raised its stake in shares of Catalyst Biosciences by 91.0% during the first quarter. Northern Trust Corp now owns 25,556 shares of the biopharmaceutical company’s stock worth $659,000 after buying an additional 12,178 shares during the last quarter. Finally, EAM Global Investors LLC bought a new stake in shares of Catalyst Biosciences during the first quarter worth approximately $644,000. 68.19% of the stock is owned by institutional investors.

CBIO opened at $9.49 on Friday. The company has a market cap of $121.82 million, a P/E ratio of -1.28 and a beta of 2.31. Catalyst Biosciences Inc has a fifty-two week low of $4.15 and a fifty-two week high of $37.00.

Catalyst Biosciences (NASDAQ:CBIO) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.08. Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 27.51%. On average, analysts predict that Catalyst Biosciences Inc will post -2.47 EPS for the current year.

Separately, Zacks Investment Research downgraded shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $19.83.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Featured Story: Exchange-Traded Funds (ETFs)

Institutional Ownership by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.